CY1106235T1 - Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων - Google Patents
Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνωνInfo
- Publication number
- CY1106235T1 CY1106235T1 CY20061101592T CY061101592T CY1106235T1 CY 1106235 T1 CY1106235 T1 CY 1106235T1 CY 20061101592 T CY20061101592 T CY 20061101592T CY 061101592 T CY061101592 T CY 061101592T CY 1106235 T1 CY1106235 T1 CY 1106235T1
- Authority
- CY
- Cyprus
- Prior art keywords
- carnitine
- protein stabilization
- stabilizing agent
- field
- proteins
- Prior art date
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 title 1
- 230000029983 protein stabilization Effects 0.000 abstract 3
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 2
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000002177 Cataract Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000012846 protein folding Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα εφεύρεση αφορά στο τεχνικό πεδίο της σταθεροποιήσεως πρωτεϊνών, συγκεκριμένα στις θεραπευτικές όψεις της σταθεροποιήσεως πρωτεϊνών. Η L-καρνιτίνη είναι ένας χρήσιμος παράγοντας στη σταθεροποίηση πρωτεϊνών, και σε μία ιδιαιτέρως ευνοϊκή όψη πρωτεϊνών χρησιμοποιούμενων στο πεδίο της ιατρικής. Σε μία προτιμώμενη όψη, η L-καρνιτίνη χρησιμοποιείται στην προστασία της συνοδευτικής δράσεως, και στο ιατρικό πεδίο στη διατήρηση της δράσεως των διαφοροποιημένων συνοδών πρωτεϊνών. Σε συνδυασμό με την παρούσα εφεύρεση η L-καρνιτίνη χρησιμοποιείται στην παρασκευή ενός φαρμάκου για την αγωγή ασθενειών που οφείλονται στις διαφοροποιημένες συνοδούς πρωτεΐνες, όπως οι ασθένειες των οφθαλμών, και συγκεκριμένα ο καταρράκτης.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IT2000/000520 WO2002048190A1 (en) | 2000-12-15 | 2000-12-15 | Use of l-carnitine as stabilizing agent of proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1106235T1 true CY1106235T1 (el) | 2011-06-08 |
Family
ID=11133601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101592T CY1106235T1 (el) | 2000-12-15 | 2006-11-03 | Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7833977B2 (el) |
| EP (1) | EP1341813B1 (el) |
| AT (1) | ATE339445T1 (el) |
| AU (1) | AU2001223953A1 (el) |
| CA (1) | CA2434911C (el) |
| CY (1) | CY1106235T1 (el) |
| DE (1) | DE60030787T2 (el) |
| DK (1) | DK1341813T3 (el) |
| ES (1) | ES2272351T3 (el) |
| HU (1) | HU230002B1 (el) |
| MX (1) | MXPA03006266A (el) |
| PL (1) | PL199984B1 (el) |
| PT (1) | PT1341813E (el) |
| SK (1) | SK287787B6 (el) |
| WO (1) | WO2002048190A1 (el) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861403B2 (en) | 2000-05-03 | 2005-03-01 | Expressive Constructs, Inc. | Method and device for improving protein stability and solubility |
| PL199984B1 (pl) | 2000-12-15 | 2008-11-28 | Sigma Tau Ind Farmaceuti | Zastosowanie L-karnityny jako czynnika stabilizującego białka |
| EP1624886A2 (en) * | 2003-05-12 | 2006-02-15 | Expressive Constructs, Inc. | Methods for increasing cell and tissue viability |
| WO2011075430A1 (en) * | 2009-12-14 | 2011-06-23 | University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| US20200140500A1 (en) * | 2012-07-17 | 2020-05-07 | The Regents Of The University Of Michigan | High throughput methods, protein inhibitors, and uses thereof |
| WO2014152818A1 (en) | 2013-03-14 | 2014-09-25 | The University Of Massachusetts | Methods of inhibiting cataracts and presbyopia |
| MX2018005903A (es) | 2015-11-13 | 2019-04-04 | Univ Massachusetts | Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1235153B (it) * | 1988-11-15 | 1992-06-22 | Sigma Tau Ind Farmaceuti | Uso dell'acetil l-carnitina nel trattamento terapeutico della cataratta e composizioni farmaceutiche utili in tale trattamento |
| US20040058015A1 (en) | 2000-06-01 | 2004-03-25 | Yuanjin Tao | Compositions and methods for treating eye discomfort and eye disease |
| PL199984B1 (pl) | 2000-12-15 | 2008-11-28 | Sigma Tau Ind Farmaceuti | Zastosowanie L-karnityny jako czynnika stabilizującego białka |
| ITRM20010294A1 (it) | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re |
| US6923960B2 (en) | 2001-10-03 | 2005-08-02 | Vsl Pharmaceuticals Inc. | Antioxidant combination composition and use thereof |
| WO2006121421A2 (en) | 2004-01-14 | 2006-11-16 | Robert Ritch | Methods and formulations for treating glaucoma |
| ITRM20040327A1 (it) | 2004-07-01 | 2004-10-01 | Sigma Tau Ind Farmaceuti | Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici. |
| US8569366B2 (en) | 2005-04-26 | 2013-10-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes |
-
2000
- 2000-12-15 PL PL367204A patent/PL199984B1/pl unknown
- 2000-12-15 PT PT00987614T patent/PT1341813E/pt unknown
- 2000-12-15 DK DK00987614T patent/DK1341813T3/da active
- 2000-12-15 EP EP00987614A patent/EP1341813B1/en not_active Expired - Lifetime
- 2000-12-15 AT AT00987614T patent/ATE339445T1/de active
- 2000-12-15 AU AU2001223953A patent/AU2001223953A1/en not_active Abandoned
- 2000-12-15 ES ES00987614T patent/ES2272351T3/es not_active Expired - Lifetime
- 2000-12-15 WO PCT/IT2000/000520 patent/WO2002048190A1/en active IP Right Grant
- 2000-12-15 US US10/470,999 patent/US7833977B2/en not_active Expired - Fee Related
- 2000-12-15 HU HU0400737A patent/HU230002B1/hu not_active IP Right Cessation
- 2000-12-15 SK SK890-2003A patent/SK287787B6/sk not_active IP Right Cessation
- 2000-12-15 CA CA002434911A patent/CA2434911C/en not_active Expired - Fee Related
- 2000-12-15 MX MXPA03006266A patent/MXPA03006266A/es active IP Right Grant
- 2000-12-15 DE DE60030787T patent/DE60030787T2/de not_active Expired - Lifetime
-
2006
- 2006-11-03 CY CY20061101592T patent/CY1106235T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0400737A3 (en) | 2013-06-28 |
| SK287787B6 (sk) | 2011-09-05 |
| PL199984B1 (pl) | 2008-11-28 |
| HUP0400737A2 (hu) | 2004-07-28 |
| AU2001223953A1 (en) | 2002-06-24 |
| PL367204A1 (en) | 2005-02-21 |
| CA2434911C (en) | 2009-12-08 |
| US7833977B2 (en) | 2010-11-16 |
| SK8902003A3 (en) | 2003-12-02 |
| EP1341813A1 (en) | 2003-09-10 |
| DE60030787T2 (de) | 2007-09-13 |
| DE60030787D1 (de) | 2006-10-26 |
| ES2272351T3 (es) | 2007-05-01 |
| WO2002048190A1 (en) | 2002-06-20 |
| HU230002B1 (en) | 2015-04-28 |
| US20040120967A1 (en) | 2004-06-24 |
| PT1341813E (pt) | 2007-01-31 |
| MXPA03006266A (es) | 2004-06-25 |
| DK1341813T3 (da) | 2007-01-15 |
| CA2434911A1 (en) | 2002-06-20 |
| ATE339445T1 (de) | 2006-10-15 |
| EP1341813B1 (en) | 2006-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119951T1 (el) | Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv | |
| CY1106235T1 (el) | Χρηση της l-καρνιτινης ως σταθepοποιητικου παραγοντα πρωτεϊνων | |
| DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| CY1121113T1 (el) | Θεραπεια της νοσου ρομρε | |
| CY1122659T1 (el) | Ενωση 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτης για μη-νοηματικη καταστολη και τη θεραπεια ασθενειας | |
| NO945103D0 (no) | Ribozym med en termodynamisk stabil lökke | |
| CY1114330T1 (el) | Πεπτιδιο ser-ser-ser-arg και ιατρικες χρησεις αυτου | |
| CY1115117T1 (el) | Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα | |
| CY1106152T1 (el) | Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids | |
| ES2249490T3 (es) | Articulos quirurgicos. | |
| CY1107143T1 (el) | Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου | |
| HUP0400882A2 (hu) | Onkolitikus vírusterápia | |
| DE60003182D1 (de) | Extendin-4 konjugate und ihre medizinische verwendung | |
| ATE477758T1 (de) | Einweg-vorrichtung zur behandlung von infektionen der menschlichen extremitäten | |
| CY1105165T1 (el) | Φαρμακευτικη συνθεση που πepιλαμβανει συνδυασμο μετφορμινης και 4-οξοβουτανικου οξεος και η χρηση αυτης για τη θepαπεια του διαβητη | |
| DE60043886D1 (de) | Formulierungen mit povidon-iod zur behandlung von wunden | |
| DK1636261T3 (da) | Thrombopoietinproteiner med forbedrede egenskaber | |
| HUP0001913A2 (hu) | Pramipexole alkalmazása állandóan mozgó láb szindróma kezelésére szolgáló gyógyszerkészítmények előállítására | |
| DE60222633D1 (de) | Verwendung von matrixprotein für gesteuerte geweberegenerationen | |
| ATE499945T1 (de) | Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose | |
| ATE405249T1 (de) | Körpergeruch verändernde biologisch aktive substanzen | |
| DE60222662D1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung | |
| DE60040910D1 (de) | Inaktivierte zytokine zur immunisierung | |
| EA200701920A1 (ru) | Использование фенилацетильных производных для производства лекарственных средств для лечения болезни фон хиппеля-линдау (vhl) | |
| DK1150981T3 (da) | Terapeutisk necleosidforbindelse |